OCS Stock Forecast & Price Target

Oculis Holding is viewed positively because its pipeline now centers on two higher-conviction catalysts: licaminlimab in dry eye disease and privosegtor in optic neuritis, both supported by encouraging clinical signals and regulatory momentum. The DED program showed statistically significant symptom improvement in Phase 2, a biomarker-enriched TNFR1 CC subgroup response, and PREDICT-1 is actively enrolling with topline data expected around end-2026, while privosegtor has SPA alignment and Breakthrough Therapy designation for ON after Phase 2 ACUITY support. Financially, the company had about $278 million in cash at 1Q-end, expected to fund operations into 2H29, giving it time to advance these potentially blockbuster neuro-ophthalmology opportunities despite the prior OCS-01/DME setback.

Oculis Holding is a high-risk biopharmaceutical company whose lead DME program, OCS-01, failed both DIAMOND-1 and DIAMOND-2 at the 52-week primary endpoint, forcing discontinuation and leaving the pipeline dependent on unproven assets. Its remaining valuation rests heavily on licaminlimab and privosegtor, yet approval probabilities are only 55% and 45%, respectively, while commercialization is still exposed to market-size, penetration, and competition risk. Financially, $282.3M of cash and a $2.38B estimated firm value may not offset rising operating expenses, reliance on third-party manufacturing, tariff exposure, and likely future dilution to fund late-stage development.